% | $
Quotes you view appear here for quick access.

Exelixis, Inc. Message Board

  • oncodoc02138 oncodoc02138 Aug 8, 2013 8:44 AM Flag

    Just read conference call transcript

    I've been very busy lately and didn't have the chance to get around to it until this morning.
    I have seen some negative sentiment again here about it; and wondering to myself, I missing something?
    1. Trials are opening and accruing on schedule per their original plan.
    2. They stated they still expect top-line data for Comet 1 and 2 in 2014.
    3. They are staggering trials to keep expensives from exploding.
    4. They continue to have great conviction in Cometriq and stated again focusing all efforts on this drug.
    5. Cash usage has expectedly gone up because they are opening and accruing to trials, this is good.
    6. They expect to still have ~$400M Cash on hand by year end.
    7. They have set up the trials to either have high likelihood for success (look at HCC trial design where there are few options for patients...#1 cancer world-wide remember) or differentiate themselves from ever more crowded space (pain benefit in prostate ca, only drug except ra223...which is a hassle to give).

    I see a well thought out strategic plan for an exciting drug. The plan appears to be going forward as expected and being executed well. The stock quite naturally is going to get day-traded until data rolls out, what fool would expect differently? This is because it is relatively cheap, there is a large float and very active share trading (typically much 1M shares traded per day)...a traders dream. Why does this bother anyone waiting for real data?

    I have never felt better about EXEL than now. My 2 cents of course, and all in my humble opinion of course, make your own judgments.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
8.7272+0.0472(+0.54%)2:44 PMEDT